Last reviewed · How we verify
Biological: IBI322
At a glance
| Generic name | Biological: IBI322 |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological: IBI322 CI brief — competitive landscape report
- Biological: IBI322 updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI